KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Liabilities (2016 - 2025)

Astrazeneca (AZN) has 3 years of Total Liabilities data on record, last reported at $65.4 billion in Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.47% year-over-year to $65.4 billion; the TTM value through Dec 2025 reached $65.4 billion, up 3.47%, while the annual FY2025 figure was $65.4 billion, 3.47% up from the prior year.
  • Total Liabilities reached $65.4 billion in Q4 2025 per AZN's latest filing, up from $63.2 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $65.4 billion in Q4 2025 and bottomed at $62.0 billion in Q4 2023.
  • Average Total Liabilities over 3 years is $63.5 billion, with a median of $63.2 billion recorded in 2024.
  • Peak YoY movement for Total Liabilities: increased 1.95% in 2024, then rose 3.47% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $62.0 billion in 2023, then rose by 1.95% to $63.2 billion in 2024, then increased by 3.47% to $65.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $65.4 billion in Q4 2025, $63.2 billion in Q4 2024, and $62.0 billion in Q4 2023.